Total Revenue
Amgen Total Revenue decreased by 12.6% to $8.62B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.8%, from $8.15B to $8.62B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 9.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $6.71B | $6.85B | $6.24B | $6.59B | $6.65B | $6.84B | $6.11B | $6.99B | $6.90B | $8.20B | $7.45B | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
| QoQ Change | — | +2.8% | +2.1% | -8.9% | +5.7% | +0.9% | +2.8% | -10.7% | +14.4% | -1.2% | +18.7% | -9.1% | +12.6% | +1.4% | +6.9% | -10.3% | +12.6% | +4.1% | +3.2% | -12.6% |
| YoY Change | — | — | — | — | +1.0% | -0.8% | -0.1% | -2.1% | +5.9% | +3.8% | +19.8% | +22.0% | +20.1% | +23.2% | +10.9% | +9.4% | +9.4% | +12.4% | +8.6% | +5.8% |
Product Breakdown — Product sales
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Other products | $1.33B | $1.36B | $1.57B | $1.65B | $1.69B | $1.85B | $2.07B | $1.53B |
| Repatha | — | — | — | — | — | — | — | $876.00M |
| Prolia | $1.17B | $1.05B | $1.17B | $1.10B | $1.12B | $1.14B | $1.05B | $727.00M |
| EVENITY | $391.00M | $399.00M | $431.00M | $442.00M | $518.00M | $541.00M | $599.00M | $562.00M |
| TEPEZZA | $479.00M | $488.00M | $460.00M | $381.00M | $505.00M | $560.00M | $457.00M | $490.00M |
| Otezla | $544.00M | $564.00M | $624.00M | $437.00M | $618.00M | $585.00M | $625.00M | $431.00M |
| BLINCYTO | $264.00M | $327.00M | $381.00M | $370.00M | $384.00M | $392.00M | $413.00M | $415.00M |
| Nplate | $346.00M | $456.00M | $337.00M | $313.00M | $369.00M | $457.00M | $385.00M | $412.00M |
| XGEVA | $562.00M | $541.00M | $561.00M | $566.00M | $532.00M | $539.00M | $447.00M | $411.00M |
| TEZSPIRE | $234.00M | $269.00M | $296.00M | $285.00M | $342.00M | $377.00M | $474.00M | $343.00M |
| KYPROLIS | — | — | — | — | — | — | — | $330.00M |
| ENBREL | $909.00M | $825.00M | $1.02B | $510.00M | $604.00M | $580.00M | $532.00M | $320.00M |
| Aranesp | $348.00M | $337.00M | $308.00M | $340.00M | $359.00M | $357.00M | $333.00M | $311.00M |
| Vectibix | $270.00M | $282.00M | $246.00M | $267.00M | $305.00M | $284.00M | $319.00M | $287.00M |
| UPLIZNA | — | — | — | — | — | — | — | $262.00M |
| IMDELLTRA/IMDYLLTRA | — | — | — | — | — | — | — | $258.00M |
| KRYSTEXXA | $294.00M | $310.00M | $346.00M | $236.00M | $349.00M | $320.00M | $435.00M | $255.00M |
| Total | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
KYPROLIS, Repatha are derived from annual filings.
Product Breakdown — BeiGene
| Segment | FY'22 | FY'23 |
|---|---|---|
| BeiGene | $64.00M | $125.00M |
| Total | $26.32B | $28.19B |
All segment values are derived from annual filings.
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Reportable Segment | $8.15B | $9.18B | $9.56B | $8.62B |
| Total | $8.15B | $9.18B | $9.56B | $8.62B |
Geographic Breakdown
| Segment | FY'22 | FY'23 |
|---|---|---|
| Non Us | $7.73B | $8.38B |
| Total | $26.32B | $28.19B |
All segment values are derived from annual filings.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Amgen's total revenue?
- Amgen (AMGN) reported total revenue of $8.62B in Q1 2026.
- How has Amgen's total revenue changed year-over-year?
- Amgen's total revenue increased by 5.8% year-over-year, from $8.15B to $8.62B.
- What is the long-term trend for Amgen's total revenue?
- Over 4 years (2021 to 2025), Amgen's total revenue has grown at a 9.1% compound annual growth rate (CAGR), from $25.98B to $36.75B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.